DNA Damage Response Inhibitor and Anti-PD-L1 Therapy for Prostate Cancer: Development of Predictive Biomarkers

查看全文 作　　者：Chuandong [1]Geng;Timothy [1]C.Thompson 机构地区：[1]Department of Genitourinary Medical Oncology,The University of Texas MD Anderson Cancer Center,Houston,TX 77030,USA 出　　处：《Engineering》索引2022年第8卷第5期,共4页 基　　金：the support from MD Anderson National Cancer Institute (NCI) Prostate Cancer SPORE (P50 CA140388);the NCI Cancer Center Support (P30 CA16672) 摘　　要：1.Introduction Although androgen receptor biosynthesis and signaling inhibi-tors have significantly improved outcomes in patients with castra-tion-resistant prostate cancer(CRPC),there is still a dearth of effective treatment options for men with advanced prostate cancer. 关 键 词：CANCER THERAPY patients